A comment on metformin and COVID‐19 with regard to “Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID‐19 patients with diabetes: A population‐based study in Lombardy”
Abstract
We congratulate Ojeda-Fernández et al 1 on their study of the association between metformin use and lower risks of hospitalization and mortality in COVID-19 patients with diabetes. The study, one of the largest yet published, emphasizes the consistency of the association between metformin use and improved COVID-19 outcomes after hospital admission and in the medium term. However, we believe the published data on this topic should be interpreted with caution. In Table 1, we present an up-to-date summary of studies on the relation-ship between metformin use and COVID-19 that (i) were published in peer-reviewed medical journals and (ii) included more than 100 patients overall and more than 50 metformin users in particular. Duplicate studies and studies published in languages other than English, French or Italian were excluded. Our analysis of this large body of published data prompted sev-eral important remarks: designs;
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.